GlassScriptPhysician profile
Aram Benjamin Loeb
NPI 1598015125
$112,054.04
in general payments reported to CMS, 2019-2025
30 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,024 · 2021: $1,154 · 2022: $18K · 2023: $16K · 2024: $32K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $33K · Consulting Fee: $28K · Food and Beverage: $7,618 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $33,153.63 |
| Consulting Fee | $28,000.20 |
| Food and Beverage | $7,617.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,240.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $97,359.34 | 2019-2025 | Titan, Virtue |
| Boston Scientific Corporation | $7,431.41 | 2019-2025 | Axonics, Ams 700, General - Therapies |
| Endo Pharmaceuticals INC. | $3,218.31 | 2019-2023 | Xiaflex, Aveed |
| Axonics, INC. | $1,825.93 | 2023-2024 | Axonics, Bulkamid |
| Antares Pharma, INC. | $392.71 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Zyla Life Sciences, INC. | $304.93 | 2019-2020 | |
| Neotract INC. | $210.85 | 2019-2020 | |
| Stryker Corporation | $188.11 | 2025 | 1788 |
| Procept Biorobotics Corporation | $158.18 | 2024 | Aquabeam System |
| Astellas Pharma US INC | $126.92 | 2019-2023 | Myrbetriq, Veozah |
| Endo USA, INC. | $112.24 | 2024 | Xiaflex |
| Tolmar, INC. | $90.82 | 2023-2025 | Eligard, Jatenzo |
| Rochester Medical Corporation | $75.22 | 2019-2021 | |
| C. R. Bard, INC. & Subsidiaries | $73.17 | 2023 | Bard Urinary Drainage Bag |
| Teleflex LLC | $67.88 | 2021-2025 | Urolift |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $47.39 | 2024-2025 | |
| Abbvie INC. | $45.87 | 2023 | |
| Olympus America INC. | $43.47 | 2022-2025 | Itind System |
| Clarus Therapeutics INC. | $38.89 | 2021 | |
| Halozyme INC | $37.41 | 2023 | |
| Rigicon,INC. | $32.95 | 2021-2023 | Rigi10 Malleable Penile Prosthesis |
| Dentsply Ih Ab | $32.54 | 2025 | Lofric |
| Sumitomo Pharma America, INC. | $31.90 | 2023 | Gemtesa |
| Allergan, INC. | $27.07 | 2021 | |
| Sagent Pharmaceuticals | $18.30 | 2022 | |
| Photocure INC | $15.93 | 2025 | Cysview |
| Dentsply Ih INC. | $14.14 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.67 | 2025 | Azmiro |
| Richard Wolf Medical Instruments Corp. | $13.50 | 2019 | |
| Ambu INC. | $4.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aram Loeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.